Cargando…

Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity

Tumor heterogeneity is the major cause of failure in cancer prognosis and prediction. Accurately detecting heterogeneity for the development of biomarkers and the detection of the clones resistant to therapy is one of the main goals of contemporary medicine. Metastases belong to the natural history...

Descripción completa

Detalles Bibliográficos
Autores principales: Tellez-Gabriel, Marta, Heymann, Marie-Françoise, Heymann, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643448/
https://www.ncbi.nlm.nih.gov/pubmed/31367241
http://dx.doi.org/10.7150/thno.34337
_version_ 1783437125119639552
author Tellez-Gabriel, Marta
Heymann, Marie-Françoise
Heymann, Dominique
author_facet Tellez-Gabriel, Marta
Heymann, Marie-Françoise
Heymann, Dominique
author_sort Tellez-Gabriel, Marta
collection PubMed
description Tumor heterogeneity is the major cause of failure in cancer prognosis and prediction. Accurately detecting heterogeneity for the development of biomarkers and the detection of the clones resistant to therapy is one of the main goals of contemporary medicine. Metastases belong to the natural history of cancer. The present review gives an overview on the origin of tumor heterogeneity. Recent progress has made it possible to isolate and characterize circulating tumor cells (CTCs), which are the drivers of the disease between the primary sites and metastatic foci. The most recent methods for characterizing CTCs are summarized and we discuss the power of CTC profiling for analyzing tumor heterogeneity in early and advanced diseases.
format Online
Article
Text
id pubmed-6643448
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-66434482019-07-31 Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity Tellez-Gabriel, Marta Heymann, Marie-Françoise Heymann, Dominique Theranostics Review Tumor heterogeneity is the major cause of failure in cancer prognosis and prediction. Accurately detecting heterogeneity for the development of biomarkers and the detection of the clones resistant to therapy is one of the main goals of contemporary medicine. Metastases belong to the natural history of cancer. The present review gives an overview on the origin of tumor heterogeneity. Recent progress has made it possible to isolate and characterize circulating tumor cells (CTCs), which are the drivers of the disease between the primary sites and metastatic foci. The most recent methods for characterizing CTCs are summarized and we discuss the power of CTC profiling for analyzing tumor heterogeneity in early and advanced diseases. Ivyspring International Publisher 2019-06-19 /pmc/articles/PMC6643448/ /pubmed/31367241 http://dx.doi.org/10.7150/thno.34337 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Tellez-Gabriel, Marta
Heymann, Marie-Françoise
Heymann, Dominique
Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity
title Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity
title_full Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity
title_fullStr Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity
title_full_unstemmed Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity
title_short Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity
title_sort circulating tumor cells as a tool for assessing tumor heterogeneity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643448/
https://www.ncbi.nlm.nih.gov/pubmed/31367241
http://dx.doi.org/10.7150/thno.34337
work_keys_str_mv AT tellezgabrielmarta circulatingtumorcellsasatoolforassessingtumorheterogeneity
AT heymannmariefrancoise circulatingtumorcellsasatoolforassessingtumorheterogeneity
AT heymanndominique circulatingtumorcellsasatoolforassessingtumorheterogeneity